Vor Biopharma Inc. (NASDAQ:VOR) Sees Large Growth in Short Interest

Vor Biopharma Inc. (NASDAQ:VOR) was the target of a large increase in short interest during the month of December. As of December 15th, there was short interest totaling 1,943,561 shares, an increase of 758.6% from the November 30th total of 226,362 shares. Based on an average daily volume of 4,925,320 shares, the short-interest ratio is presently 0.4 days. Approximately 18.8% of the company’s stock are short sold. Approximately 18.8% of the company’s stock are short sold. Based on an average daily volume of 4,925,320 shares, the short-interest ratio is presently 0.4 days.

Vor Biopharma Price Performance

VOR traded up $1.00 during trading on Wednesday, reaching $14.53. 850,483 shares of the company’s stock were exchanged, compared to its average volume of 698,855. The company has a market cap of $151.22 million, a P/E ratio of -0.04 and a beta of 2.08. The firm has a 50 day moving average of $15.46. Vor Biopharma has a fifty-two week low of $2.62 and a fifty-two week high of $65.80.

Insiders Place Their Bets

In other Vor Biopharma news, Director Ra Capital Management, L.P. sold 24,579 shares of the stock in a transaction on Thursday, October 30th. The shares were sold at an average price of $25.12, for a total transaction of $617,424.48. Following the transaction, the director directly owned 779,652 shares of the company’s stock, valued at $19,584,858.24. This represents a 3.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Reprogrammed Interchange Llc sold 11,616 shares of the business’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $30.05, for a total value of $349,060.80. Following the completion of the sale, the insider directly owned 1,167,109 shares of the company’s stock, valued at $35,071,625.45. This represents a 0.99% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 1,674,800 shares of company stock valued at $49,516,960 over the last quarter. 0.45% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in VOR. Goldman Sachs Group Inc. lifted its stake in Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after purchasing an additional 58,247 shares during the period. XTX Topco Ltd bought a new stake in shares of Vor Biopharma in the 2nd quarter valued at approximately $66,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Vor Biopharma in the 1st quarter worth approximately $100,000. Jane Street Group LLC bought a new position in shares of Vor Biopharma during the 1st quarter worth approximately $140,000. Finally, Squarepoint Ops LLC acquired a new stake in Vor Biopharma in the 3rd quarter valued at $230,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Analyst Ratings Changes

VOR has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, October 8th. Zacks Research raised Vor Biopharma from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 11th. Baird R W raised Vor Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 15th. Wedbush assumed coverage on shares of Vor Biopharma in a research note on Tuesday, November 25th. They issued a “neutral” rating on the stock. Finally, HC Wainwright dropped their target price on shares of Vor Biopharma from $55.00 to $32.00 and set a “buy” rating on the stock in a research report on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $68.43.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).